Open AccessSafety and efficacy of twice daily administration of KPI-121 1% for ocular inflammation and pain following cataract surgery
Author(s) -
Terry Kim,
Kenneth Sall,
Edward J. Holland,
Romulus K. Brazzell,
Susan Coultas,
Preeya K. Gupta
Publication year - 2018
Publication title -
clinical ophthalmology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.025
H-Index - 56
eISSN - 1177-5483
pISSN - 1177-5467
DOI - 10.2147/opth.s185800
Subject(s) - medicine , cataract surgery , ophthalmology , inflammation , anesthesia , surgery
KPI-121 is a nanoparticle suspension of loteprednol etabonate with improved ocular pharmacokinetics compared with marketed formulations. The efficacy and safety of KPI-121 1% ophthalmic suspension (INVELTYS™) dosed twice daily (BID) were evaluated in participants who had undergone cataract surgery.